Spyglass Pharma Inc (SGP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2001 | 12-2000 | |
| Sales | 9,762,000 | 9,775,000 |
| Cost of Goods | 2,078,000 | 1,902,000 |
| Gross Profit | 7,684,000 | 7,873,000 |
| Operating Expenses | 4,756,000 | 4,778,000 |
| Operating Income | 2,928,000 | 3,095,000 |
| Other Income | -405,000 | 93,000 |
| Pre-tax Income | 2,523,000 | 3,188,000 |
| Income Tax | 580,000 | 765,000 |
| Net Income Continuous | 1,943,000 | 2,423,000 |
| Net Income | $1,943,000 | $2,423,000 |
| EPS Basic Total Ops | 1.33 | 1.65 |
| EPS Basic Continuous Ops | 1.33 | 1.65 |
| EPS Diluted Total Ops | 1.32 | 1.64 |
| EPS Diluted Continuous Ops | 1.32 | 1.64 |
| EBITDA(a) | $3,248,000 | $3,394,000 |